



# Biotech Daily

Monday August 30, 2021

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: IMUGENE UP 10%; AMPLIA DOWN 5%**
- \* **MEDADVISOR REVENUE UP 304% TO \$39m, LOSS UP 49% TO \$15.4m**
- \* **AUSTCO REVENUE DOWN 1% TO \$31m, PROFIT UP 37% TO \$3m**
- \* **LUMOS REVENUE UP 198% TO \$25m, LOSS UP 50% TO \$20m**
- \* **NEXT SCIENCE H1 REVENUE UP 272% TO \$5.4m, LOSS DOWN 37% TO \$4m**
- \* **IMEX H1 REVENUE UP 15% TO \$5.2m, LOSS UP 18% TO \$3m**
- \* **RESONANCE REVENUE UP 3% TO \$3.8m, LOSS TO \$586k PROFIT**
- \* **IQ3 REVENUE DOWN 58% TO \$3m, LOSS UP 156% TO \$6m**
- \* **ORTHOCELL REVENUE UP 48% TO \$1m, LOSS UP 47% TO \$9m**
- \* **FEDERAL DISER APPROVES NEUREN OVERSEAS R&D; EXPECTS \$6.5m**
- \* **ANTERIS EXTENDS LEMAITRE MANUFACTURING DEAL**
- \* **ALTHEA PLEADS SCHULTZ TO ASX LISTING RULE 15.7 LEAK QUERY**
- \* **IMRICOR TO SELL NORDICNEUROLAB MONITORS**
- \* **ASX REMOVES TBG FROM OFFICIAL LIST**
- \* **CREDIT SUISSE BELOW 5% OF IDT**
- \* **MERCHANT REDUCES, DILUTED TO 12.6% OF BARD1**
- \* **SG HISCOCK TAKES 9.6% OF BOD**
- \* **CHIMERIC APPOINTS JENNIFER CHOW CEO, M-D; STARTS ON \$754k**
- \* **DAVID AUSTIN REPLACES CANN GLOBAL CHAIR PNINA FELDMAN**

## MARKET REPORT

The Australian stock market was up 0.22 percent on Monday August 30, 2021, with the ASX200 up 16.2 points to 7,504.5 points. Nineteen of the Biotech Daily Top 40 stocks were up, 13 fell, seven traded unchanged and one was untraded.

Imugene was the best, up 3.5 cents or 10.1 percent to 38 cents, with 38.3 million shares traded. Pharmaxis climbed 9.1 percent; Polynovo was up 7.5 percent; Kazia improved 5.1 percent; Avita, LBT, Proteomics and Universal Biosensors were up four percent or more; Alterity, Dimerix, Paradigm and Starpharma climbed more than three percent; Actinogen, Antisense, Compumedics and Oncosil rose more than two percent; Cyclopharm and Neuren were up more than one percent; with Cochlear and Mesoblast up by less than one percent.

Amplia the falls, down one cent or 4.9 percent to 19.5 cents, with 52,873 shares traded. Orthocell fell 4.1 percent; Cynata, Genetic Signatures and Prescient shed more than two percent; Clinuvel, Nanosonics, Next Science, Opthea, Resmed, Telix and Volpara were down more than one percent; with CSL, Medical Developments and Pro Medicus down by less than one percent.

## MEDADVISOR

Medadvisor says revenue for the year to June 30, 2021, was up 303.8 percent to \$38,772,576 with net loss after tax up 58.8 percent to \$15,444,523.

Medadvisor said that the inclusion of Adheris LLC, which Medadvisor acquired last year, added to both revenue and the increased net loss after tax (BD: Nov 2, 12, 2020).

The company said since the acquisition, it had invested in sales and marketing, research and development and personnel to add digital capabilities, and additional scale to open larger addressable markets.

Medadvisor said that revenue came from its pharmacy prescription reminder service.

The company said that its diluted loss per share was up 7.6 percent to 4.54 cents.

Medadvisor said that net tangible asset backing per share negative 2.13 cents compared with last year's 4.34 cents, and it had cash and cash equivalents of \$7,150,865 at June 30, 2021 compared to \$12,345,164 at June 30, 2020.

Medadvisor fell 2.5 cents or 6.9 percent to 33.5 cents.

## AUSTCO HEALTHCARE (FORMERLY AZURE HEALTHCARE)

Austco says revenue for the year to June 30, 2021, was down 1.1 percent to \$31,250,000 with profit after tax up 36.7 percent \$3,424,000.

Austco said its revenue came from sales of its Tacera and Pulse branded healthcare communications and clinical workflow systems.

The company said uncertainty persisted regarding the potential impact on revenue for 2021-'22 due to Covid-19.

The company said diluted earnings per share was up 25.1 percent to 1.201 cents, with net tangible assets per share up 20.2 percent to 4.99 cents, and it had cash and cash equivalents of \$7,770,000 at June 30, 2021 compared to \$6,447,000 at June 30, 2020.

Austco was unchanged at 14 cents.

### LUMOS DIAGNOSTICS

Lumos says revenue for the year to June 30, 2021, was up 198.4 percent to \$25,055,000 with net loss after tax up 49.7 percent to \$20,127,000.

Lumos said revenue came primarily from its point-of-care diagnostic products, point-of-care readers, commercial and manufacturing services, with the sale of its first Lumos-branded point-of-care diagnostic test Febridx gaining momentum in 2020-'21.

The company said the increase was driven by the Covid-19 pandemic, which resulted in an unprecedented demand for point-of-care test development services and products.

Lumos said that diluted loss per share was up 26.1 percent to 76.39 cents, net tangible asset backing per share was up from 2.84 cents last year to 28.87 cents at June 30, 2021, and it had cash and cash equivalents of \$59,710,000 at June 30, 2021 compared to \$1,233,000 at June 30, 2020.

Lumos fell two cents or 1.7 percent to \$1.18.

### NEXT SCIENCE

Next Science says revenue for the six months to June 30, 2021, was up 271.5 percent to \$US3,914,671 (\$A5,355,368) with net loss after tax down 37.3 percent to \$US4,199,059 (\$A5,744,418).

Next Science said revenue from wound care products Bactisure, Surgx, Blastx and Xperience, included \$US3,837,089 from sales in the US and \$US77,582 from Australia.

The company said diluted loss per share fell 42.2 percent to 2.14 US cents, net tangible asset backing per share rose 20.2 percent to 6.91 US cents, with cash and equivalents of \$US6,934,276 at June 30, 2021, compared to \$US11,907,362 at June 30, 2020.

Next Science fell two cents or 1.4 percent to \$1.42.

### IMEX HEALTH SERVICES

Imex says revenue for the six months to June 30, 2021 was up 14.9 percent to \$5,158,811 with net loss after tax up 17.5 percent to \$2,775,619.

Imex said revenue came from sales, licencing and leasing of its internet-based Aquila radiology platform, and in the half year about 54 percent of sales was to one customer.

The company said diluted loss per share was down 8.1 percent to 9.2 cents with net tangible assets per share down 18.3 percent to 39.69 cents and it had cash and cash equivalents of \$8,342,337 at June 30, 2021 compared to \$6,293,533 at June 30, 2020.

Imex fell six cents or 3.9 percent to \$1.49.

### RESONANCE HEALTH

Resonance says revenue for the year to June 30, 2021, was up 3.0 percent to \$3,778,914 with last year's \$715,076 net loss after tax turned to profit of \$585,858.

Resonance said revenue came from its magnetic resonance imaging (MRI)-based Ferriscan liver iron concentrate diagnostic, as well as Hepafat and the Cardiac T2\* and increased clinical trial contracts, with 31 percent of revenue from North America, 21 percent from the UK, with the remainder from Australia, Asia, Europe and the Middle East. The company said that it had diluted earnings per share of 0.13 cents compared to diluted loss per share of 0.17 cents in the previous corresponding period, with net tangible assets per share up 20.5 percent to 2.00 cents and it had cash and cash equivalents of \$8,856,820 at June 30, 2021 compared to \$6,974,237 at June 30, 2020.

Resonance was unchanged at 12 cents.

### IQ3 CORP

IQ3 says that revenue for the year to June 30, 2021, was down 58.0 percent to \$2,897,311, with net loss after tax up 156.1 percent to \$5,666,365.

IQ3 said that revenue came its life science corporate finance and advisory services.

The company said that diluted loss per share was up 155.4 percent to 5.44 cents.

IQ3 said that net tangible assets per share was negative 6.69 cents compared to negative 1.25 cents last year.

The company said that it had cash and cash equivalents of \$239,356 at June 30, 2021 compared to \$227,377 at June 30, 2020.

IQ3 was untraded at 15 cents.

### ORTHOCELL

Orthocell said revenue for the year to June 30, 2021, was up 47.5 percent to \$1,017,962 with net loss after tax up 46.9 percent to \$9,037,025.

Orthocell said revenue was from its Striate Celgro dental bone collagen regeneration therapy, the Ortho-autologous chondrocyte implantation (Ortho-ACI), as well as income from its Ortho-autologous tenocyte implantation (Ortho-ATI) through a special access scheme.

The company said that diluted loss per share was up 30.6 percent to 4.7 cents.

Orthocell said that net tangible assets per share was down 21.8 percent to 8.16 cents, and it had cash and cash equivalents of \$16,328,913 at June 30, 2021 compared to \$20,441,616 at June 30, 2020.

Orthocell fell two cents or 4.1 percent to 46.5 cents.

### NEUREN PHARMACEUTICALS

Neuren says the Federal Department of Industry has approved its Research and Development Tax Incentive off-shore claims and it expects to receive up to \$6.5 million.

Neuren said that the approval, through Ausindustry related to the development of NNZ-2591 for neuro-developmental disorders and eligible research and development expenditure incurred over 2020, 2021 and 2022.

Neuren was up three cents or 1.4 percent to \$2.22.

### ANTERIS TECHNOLOGIES (FORMERLY ADMEDUS)

Anteris says it has signed a further agreement with LeMaitre Vascular to extend its manufacturing of Cardiocel and Vascucel at its Malaga facility in Western Australia.

Anteris said the agreement included a nine-month extension to the current manufacturing contract, for the Adapt-treated tissue repair technologies, which would conclude in July 2023.

In 2019, the then Admedus said it sold the distribution rights for Cardiocel and Vascucel to LeMaitre Vascular for up to \$36.2 million (BD: Oct 14, 2019).

Today, Anteris said LeMaitre would assume the responsibility for applying for the regulatory approvals under European Medical Devices Directorate Regulation.

Anteris said the associated costs would also be assumed by LeMaitre and deducted from the \$3 million earn-out and payable in instalments on receipt of each European product approval.

Anteris was up five cents or 0.6 percent to \$9.00.

## ALTHEA GROUP HOLDINGS

Althea has told the ASX is not aware how information about its \$90 million capital raise appeared in a news article.

This is the third such ASX query in two weeks (see below).

The ASX said that Althea requested a trading halt on August 23 “pending the release of an announcement regarding a capital raise” at 8.32am (AEST).

The ASX said that and an article titled ‘Canaccord tapped for Althea’s \$10.7m raising’ was published by the Australian Financial Review at 10:24am (AEST) on the same day, which contained details of the capital raising.

The ASX said that Althea announced the \$10.64 million placement on August 25, 2021 and asked how the information in the announcement appeared in the article and what arrangements it had to ensure compliance with Listing Rule 15.7, prohibiting the provision of information to any party prior to the ASX.

In its reply, Althea told the ASX that it had “no knowledge about how the information contained in the article was obtained by the Australian Financial Review”.

“Althea confirms that it did not provide the information in the article to the Australian Financial Review, nor did it authorize the information for release to the Australian Financial Review, whether on an embargoed basis or otherwise,” the company said.

Althea said that it “ensures each of its engagements with its advisors and service providers have confidentiality provisions to ensure compliance with 15.7”.

Last week, Imugene told the ASX was not aware how information about its \$90 million capital raise appeared in a news article (BD: Aug 24, 2021).

The ASX said that Imugene requested a trading halt on July 27 “pending an announcement in relation to a capital raising” at 8.44am (AEST) and an article titled ‘Paul Hopper’s biotech Imugene hunts \$85m’ was published by the Australian Financial Review at 10:15am (AEST) on July 27, which contained details of the capital raising.

The ASX said Imugene announced the \$90 million placement and \$5 million share plan on July 29, 2021 and asked how the information in the announcement appeared in the article and what arrangements it had to ensure compliance with Listing Rule 15.7, prohibiting the provision of information to any party prior to the ASX.

In its reply, Imugene told the ASX that the detail of the article was “scarce on pricing and inaccurate on the amount raised”.

“The article appears to be speculative street talk” based on the trading halt, Imugene said. Imugene told the ASX that the company, or officers of the company, were not consulted and did not have contact with the journalist in relation to the article.

In July, Imugene said its placement was led by Bell Potter Securities.

Earlier this month, Dimerix told the ASX it had nothing to do with a leak to the Australian Financial Review about its \$20 million placement (BD: Aug 16, 19, 2021).

In response to a similar ASX query, Dimerix said that neither it, nor any of its officers, had contact with the Financial Review and it was not aware of how the information in the announcement was sourced and appeared in the article, which “was published without the knowledge of the company”.

Dimerix said that Canaccord Genuity (Australia) was the lead manager to the raising and began a process of “wall-crossing”, providing certain institutional and sophisticated investors confidential information after the trading halt “in line with industry standards”.

“It may be that the information which appeared in the article, was initially disclosed by such person with whom the deal term sheet was shared in the wall-crossing process,”

Dimerix said.

In July, Imugene said its placement was led by Bell Potter Securities.

Althea fell half a cent or two percent to 24.5 cents with two million shares traded.

### IMRICOR

Imricor says it will sell the Bergen, Norway-based NordicneuroLab's magnetic resonance imaging (MRI) compatible in-room monitors.

Imricor said it would be a non-exclusive distributor of NordicNeuroLab's in room viewing device, which was a 40-inch MRI-compatible monitor for use in the magnet room of a cardiac magnetic resonance imaging laboratory.

The company did not state any financial terms.

Imricor fell 4.5 cents or 3.7 percent to \$1.18.

### TBG DIAGNOSTICS

The ASX says that TBG Diagnostics failed to pay the annual listing fees for the year ending June 30, 2022 and has been removed from the Official List.

Last week the ASX said the suspended company had been suspended for not paying its listing fees.

TBG has been in an ASX suspension since last year, relating to claims regarding a severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) and Covid-19 test and last traded at 27 cents (BD: Mar 19, 2020).

### IDT AUSTRALIA

Credit Suisse says it has ceased to be a substantial shareholder in IDT Australia.

The Sydney-based Credit Suisse said it bought and sold shares between August 24 and 25, 2021, with the single largest sale 1,867,775 shares for \$1,286,826 or 69 cents a share.

IDT fell seven cents or 9.4 percent to 67.5 cents with 5.96 million shares traded.

### BARD1 LIFE SCIENCES

Merchant Funds says its substantial holding in Bard1 has been reduced and diluted from 11,636,358 shares (14.48%) to 11,610,762 shares (12.63%).

Merchant Funds managing director Andrew Chapman said the company bought and sold shares between March 16, 2021 and July 27, 2021 at prices ranging from \$1.55 and \$4.18 per share, and it was diluted "due to various share issues" between March 2 and August 24, 2021.

In July, Bard1 said it raised \$18.4 million in a placement and a share plan at \$1.55 a share (BD: Jul 23, 2021).

Bard1 fell 3.5 cents or 2.4 percent to \$1.415.

### BOD AUSTRALIA

SG Hiscock says it has increased its substantial share-holding in Bod Australia from 7,860,208 shares (8.60%) to 10,201,728 shares (9.64%).

SG Hiscock said that on August 12, 2021, the company bought 2,341,520 shares for \$1,138,680 or 49 cents a share.

Bod was up 1.5 cents or 5.3 percent to 30 cents.

## CHIMERIC THERAPEUTICS

Chimeric says it has appointed Jennifer Chow as its chief executive officer and managing-director, starting on \$US550,000 (\$A753,533) plus incentives.

Chimeric said Ms Chow had been chief operating officer of Chimeric since November 2020 and previously was Kite Pharmaceuticals head of marketing and formerly worked for Roche, Nycomed/Takeda and Schering Canada.

The company said Ms Chow had more than 20 years of commercial strategy and marketing experience focused on cellular therapy, haematology, and oncology.

Chimeric said Ms Chow would have a total fixed remuneration of \$US550,000, and an industry standard health benefits package and, subject to shareholder approval, Ms Chow would be issued with 2,000,000 options exercisable at 34 cents each, vesting over three years, expiring five years from issue.

Chimeric fell half a cent or 1.6 percent to 31.5 cents.

## CANN GLOBAL

Cann Global says Pnina Feldman has retired as director and chair, with David Austin appointed independent non-executive chair, effective from today, August 30, 2021.

Cann Global said that Ms Feldman founded the company in 2007.

The company said that Mr Austin was a Sydney solicitor and had been a Cann Global director for two years.

Cann Global said that concurrent with Ms Feldman's retirement, it had terminated its arrangements with Australian Gemstone Mining Pty Ltd, a related party of Ms Feldman, which had provided executive, corporate, technical and other services, including Ms Feldman's services as an executive, and would issue 70,000,000 shares, subject to shareholder approval at the annual general meeting held in November 2021.

The company said that Ms Feldman's son Sholom Feldman continued as its chief executive officer.

Cann Global was unchanged at 0.45 cents with 21.7 million shares traded.